Analyst Reco. SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
45.11 ^USD	+4.06%		-0.92%	+23.59%

02/05	Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating	MT
02/05	SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating	02/05	MT
JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating	06/03	MT
HC Wainwright Raises Price Target on SpringWorks Therapeutics to $74 From $73, Maintains Buy Rating	06/03	MT
Wedbush Raises SpringWorks Therapeutics' PT to $70 From $60, Increases Sales Estimates for Ogsiveo, Mirdametinib; Keeps Outperform Rating	26/02	MT
Wedbush Raises SpringWorks Therapeutics' PT to $60 From $45 on Increased Valuation for Ogsiveo in Desmoid Tumors; Keeps Outperform Rating	07/02	MT
Barclays Adjusts Price Target on SpringWorks to $47 From $41, Keeps Overweight Rating	25/01	MT
Goldman Sachs Raises Price Target on SpringWorks Therapeutics to $52 From $47, Maintains Buy Rating	29/11	MT
HC Wainwright Adjusts Price Target on SpringWorks Therapeutics to $73 From $64, Keeps Buy Rating	29/11	MT
HC Wainwright Raises SpringWorks Therapeutics' Price Target to $64 From $52, Buy Rating Kept	28/11	MT
HC Wainwright Adjusts SpringWorks Therapeutics' Price Target to $52 From $58, Maintains Buy Rating	20/11	MT
HC Wainwright Adjusts Price Target on SpringWorks Therapeutics to $58 From $66, Maintains Buy Rating	09/11	MT
HC Wainwright Adjusts Price Target on SpringWorks Therapeutics to $66 From $105, Keeps Buy Rating	07/23/07	MT
Goldman Sachs Adjusts Price Target on SpringWorks Therapeutics to $49 From $43, Maintains Buy Rating	20/23/20	MT
Barclays Adjusts Price Target on SpringWorks Therapeutics to $41 From $55, Keeps Overweight Rating	28/23/28	MT
JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $57 From $53, Maintains Overweight Rating	07/23/07	MT
HC Wainwright Adjusts SpringWorks Therapeutics Price Target to $105 From $99, Maintains Buy Rating	07/23/07	MT
Goldman Sachs Raises SpringWorks Therapeutics' Price Target to $45 From $40, Maintains Buy Rating	26/23/26	MT
BofA Securities Starts SpringWorks Therapeutics at Buy With $45 Price Target	01/22/01	MT
Wedbush Cuts SpringWorks Therapeutics' Price Target to $45 From $52, Keeps Outperform Rating	23/22/23	MT
HC Wainwright Adjusts Price Target on SpringWorks Therapeutics to $99 From $103, Maintains Buy Rating	04/22/04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Analyst Reco.

Filters